DE69737956D1 - CD8 Tuberkulose Impfstoffe - Google Patents
CD8 Tuberkulose ImpfstoffeInfo
- Publication number
- DE69737956D1 DE69737956D1 DE69737956T DE69737956T DE69737956D1 DE 69737956 D1 DE69737956 D1 DE 69737956D1 DE 69737956 T DE69737956 T DE 69737956T DE 69737956 T DE69737956 T DE 69737956T DE 69737956 D1 DE69737956 D1 DE 69737956D1
- Authority
- DE
- Germany
- Prior art keywords
- tuberculosis vaccines
- vaccines
- tuberculosis
- epitopes
- esat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960002109 tuberculosis vaccine Drugs 0.000 title 1
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 abstract 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9624456.1A GB9624456D0 (en) | 1996-11-25 | 1996-11-25 | Assay method |
GB9624456 | 1996-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69737956D1 true DE69737956D1 (de) | 2007-09-06 |
DE69737956T2 DE69737956T2 (de) | 2008-04-17 |
Family
ID=10803428
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69710360T Expired - Lifetime DE69710360T3 (de) | 1996-11-25 | 1997-11-25 | Testverfahren für peptidspezifische t-zellen |
DE69737956T Expired - Lifetime DE69737956T2 (de) | 1996-11-25 | 1997-11-25 | CD8 Tuberkulose Impfstoffe |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69710360T Expired - Lifetime DE69710360T3 (de) | 1996-11-25 | 1997-11-25 | Testverfahren für peptidspezifische t-zellen |
Country Status (11)
Country | Link |
---|---|
US (3) | US7575870B1 (de) |
EP (2) | EP0941478B2 (de) |
JP (1) | JP4094674B2 (de) |
AT (2) | ATE368052T1 (de) |
AU (1) | AU728357C (de) |
CA (1) | CA2272881C (de) |
DE (2) | DE69710360T3 (de) |
DK (2) | DK0941478T4 (de) |
ES (1) | ES2172773T5 (de) |
GB (1) | GB9624456D0 (de) |
WO (1) | WO1998023960A1 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624456D0 (en) | 1996-11-25 | 1997-01-15 | Isis Innovation | Assay method |
CA2348475A1 (en) * | 1998-11-04 | 2000-05-11 | Isis Innovation Limited | Tuberculosis diagnostic test |
US20020131976A1 (en) | 1998-12-23 | 2002-09-19 | Ajit Lalvani | Tuberculosis vaccine |
GB9923306D0 (en) | 1999-10-01 | 1999-12-08 | Isis Innovation | Diagnostic and therapeutic epitope, and transgenic plant |
GB0006692D0 (en) * | 2000-03-20 | 2000-05-10 | Glaxo Group Ltd | Epitopes |
WO2001078775A2 (en) * | 2000-04-12 | 2001-10-25 | Wisconsin Alumni Research Foundation | A method for making an hiv vaccine |
EP1390755B1 (de) | 2001-01-08 | 2012-10-10 | Isis Innovation Limited | Verfahren zu bestimmung der wirksamkeit der behandlung von mycobakteriellen infektionen |
DE10125730A1 (de) * | 2001-05-17 | 2002-11-21 | A I D Autoimmun Diagnostika Gm | Verfahren zum Nachweis von Erregern und durch diese induzierten zellulär produzierten Stoffen im lebenden Organismus |
GB0212885D0 (en) | 2002-06-05 | 2002-07-17 | Isis Innovation | Therapeutic epitopes and uses thereof |
NZ545364A (en) * | 2003-09-05 | 2009-06-26 | Genencor Int | HPV CD8+ T-cell epitopes |
ITRM20040091A1 (it) * | 2004-02-19 | 2004-05-19 | Istituto Naz Per Le Malattie | Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare. |
US10105437B2 (en) | 2004-04-28 | 2018-10-23 | Btg International Limited | Epitopes related to coeliac disease |
EP2412380B1 (de) | 2004-04-28 | 2021-01-06 | BTG International Limited | Epitope im Zusammenhang mit Zöliakie |
EP1781313A4 (de) | 2004-06-17 | 2009-08-26 | Beckman Coulter Inc | Mycobacterium tuberculosis epitope und anwendungsverfahren dafür |
GB0605474D0 (en) * | 2006-03-17 | 2006-04-26 | Isis Innovation | Clinical correlates |
GB0619853D0 (en) * | 2006-10-06 | 2006-11-15 | Oxford Immunotec Ltd | Preparation method |
DE102007052517A1 (de) | 2007-10-29 | 2009-04-30 | Autoimmun Diagnostika Gmbh | ELISPOT-Verfahren mit zwei Filtersystemen |
GB2455108A (en) * | 2007-11-28 | 2009-06-03 | Circassia Ltd | T-Cell dependent method for detecting non-allergic or intrinsic disorders |
EP2385371B1 (de) | 2008-09-22 | 2014-10-22 | Oregon Health and Science University | Verfahren zum Erkennen einer Infektion mit dem Mycobakterium tuberculosis |
GB0906215D0 (en) | 2009-04-09 | 2009-05-20 | Lalvani Ajit | Diagnostic test |
US8961989B2 (en) | 2009-11-20 | 2015-02-24 | Oregon Health & Science University | Methods for producing an immune response to tuberculosis |
IT1403092B1 (it) | 2010-12-01 | 2013-10-04 | Univ Degli Studi Modena E Reggio Emilia | Metodo per la diagnosi e/o il monitoraggio della mucormicosi. |
EP2667811B1 (de) | 2011-01-27 | 2015-12-30 | Cryosa, Llc | Vorrichtung zur behandlung von obstruktiver schlafapnoe durch kryolyse von adipösen geweben |
FR2983213B1 (fr) | 2011-11-30 | 2015-03-06 | Commissariat Energie Atomique | Procede de mesure en temps reel des secretions individuelles d'une cellule |
GB201122297D0 (en) | 2011-12-23 | 2012-02-01 | Retroscreen Virology Ltd | Vaccine - screening method |
EP2795321A2 (de) * | 2011-12-23 | 2014-10-29 | Retroscreen Virology Ltd | Impfstoffscreeningverfahren |
US9678071B2 (en) | 2012-01-12 | 2017-06-13 | Mayo Foundation For Medical Education And Research | Detecting latent tuberculosis infections |
EP2828656B1 (de) * | 2012-03-23 | 2019-09-18 | Fundació Privada Institut de Recerca de la SIDA-Caixa | Verfahren zur überwachung hiv-spezifischer t-zell-antworten |
US10401360B2 (en) | 2013-04-29 | 2019-09-03 | Mayo Foundation For Medical Education And Research | Flow cytometry assay methods |
WO2015164747A1 (en) | 2014-04-24 | 2015-10-29 | Immusant, Inc. | Methods for diagnosing celiac disease using circulating cytokines/chemokines |
EP3200736B8 (de) | 2014-10-01 | 2020-06-17 | CryOSA, Inc. | Vorrichtung zur behandlung von obstruktiver schlafapnoe durch kryolyse von adipösen geweben |
CA2968422A1 (en) | 2014-11-21 | 2016-05-26 | Immusant, Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
FR3033333A1 (fr) | 2015-03-06 | 2016-09-09 | Commissariat Energie Atomique | Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations |
BR112019005732A2 (pt) | 2016-09-22 | 2019-08-06 | Pace Diagnostics Inc | proteínas de mycobacterium tuberculosis em ensaios e dispositivos de diagnóstico para a detecção e o diagnóstico da tuberculose |
US10245320B2 (en) | 2016-09-30 | 2019-04-02 | Enzo Biochem, Inc. | Immunomodulatory pharmaceutical compositions and methods of use thereof |
ES2950436T3 (es) | 2016-12-14 | 2023-10-10 | Becton Dickinson Co | Métodos y composiciones para obtener una valoración de tuberculosis en un sujeto |
WO2019018607A1 (en) | 2017-07-20 | 2019-01-24 | Enzo Biochem, Inc. | IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF |
KR102182555B1 (ko) * | 2019-03-14 | 2020-11-24 | 한국과학기술연구원 | T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼 |
CN111856020B (zh) * | 2020-06-19 | 2022-09-27 | 南方医科大学南方医院 | 乙型肝炎病毒(hbv)特异性t细胞检测方法及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005400A1 (en) | 1986-03-06 | 1987-09-11 | Commonwealth Scientific And Industrial Research Or | In vitro assay for detecting cell-mediated immune responses |
US5955077A (en) | 1993-07-02 | 1999-09-21 | Statens Seruminstitut | Tuberculosis vaccine |
DK79893D0 (da) | 1993-07-02 | 1993-07-02 | Statens Seruminstitut | New vaccine |
US20020136733A1 (en) | 1994-03-31 | 2002-09-26 | Hill Adrian Vivian Sinton | Malaria peptides |
AU6280596A (en) * | 1995-06-15 | 1997-01-15 | University Of Victoria Innovation And Development Corporation | Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides |
DE19525784A1 (de) * | 1995-07-14 | 1997-01-16 | Boehringer Mannheim Gmbh | Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD) |
US6410252B1 (en) | 1995-12-22 | 2002-06-25 | Case Western Reserve University | Methods for measuring T cell cytokines |
US5939281A (en) | 1996-09-16 | 1999-08-17 | Case Western Reserve University | Detecting alloreactivity |
GB9624456D0 (en) | 1996-11-25 | 1997-01-15 | Isis Innovation | Assay method |
CA2348475A1 (en) * | 1998-11-04 | 2000-05-11 | Isis Innovation Limited | Tuberculosis diagnostic test |
US20020131976A1 (en) | 1998-12-23 | 2002-09-19 | Ajit Lalvani | Tuberculosis vaccine |
EP1390755B1 (de) | 2001-01-08 | 2012-10-10 | Isis Innovation Limited | Verfahren zu bestimmung der wirksamkeit der behandlung von mycobakteriellen infektionen |
GB0215710D0 (en) * | 2002-07-05 | 2002-08-14 | Isis Innovation | Diagnostic method |
-
1996
- 1996-11-25 GB GBGB9624456.1A patent/GB9624456D0/en active Pending
-
1997
- 1997-11-25 DK DK97913336T patent/DK0941478T4/da active
- 1997-11-25 EP EP97913336A patent/EP0941478B2/de not_active Expired - Lifetime
- 1997-11-25 EP EP01109298A patent/EP1152012B1/de not_active Expired - Lifetime
- 1997-11-25 DE DE69710360T patent/DE69710360T3/de not_active Expired - Lifetime
- 1997-11-25 AT AT01109298T patent/ATE368052T1/de not_active IP Right Cessation
- 1997-11-25 DE DE69737956T patent/DE69737956T2/de not_active Expired - Lifetime
- 1997-11-25 DK DK01109298T patent/DK1152012T3/da active
- 1997-11-25 CA CA002272881A patent/CA2272881C/en not_active Expired - Lifetime
- 1997-11-25 JP JP52441098A patent/JP4094674B2/ja not_active Expired - Lifetime
- 1997-11-25 AT AT97913336T patent/ATE213068T1/de active
- 1997-11-25 AU AU50632/98A patent/AU728357C/en not_active Expired
- 1997-11-25 WO PCT/GB1997/003222 patent/WO1998023960A1/en active IP Right Grant
- 1997-11-25 ES ES97913336T patent/ES2172773T5/es not_active Expired - Lifetime
-
2000
- 2000-01-13 US US09/308,725 patent/US7575870B1/en not_active Expired - Fee Related
-
2009
- 2009-07-28 US US12/510,594 patent/US8617821B2/en not_active Expired - Fee Related
-
2013
- 2013-11-26 US US14/090,221 patent/US9360480B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK1152012T3 (da) | 2007-11-26 |
EP0941478A1 (de) | 1999-09-15 |
ES2172773T5 (es) | 2008-01-16 |
ATE213068T1 (de) | 2002-02-15 |
AU5063298A (en) | 1998-06-22 |
DK0941478T3 (da) | 2002-07-01 |
EP0941478B2 (de) | 2007-06-06 |
EP0941478B1 (de) | 2002-02-06 |
CA2272881A1 (en) | 1998-06-04 |
AU728357C (en) | 2001-11-01 |
US7575870B1 (en) | 2009-08-18 |
US8617821B2 (en) | 2013-12-31 |
ES2172773T3 (es) | 2002-10-01 |
DK0941478T4 (da) | 2007-10-08 |
CA2272881C (en) | 2007-10-09 |
GB9624456D0 (en) | 1997-01-15 |
EP1152012A1 (de) | 2001-11-07 |
US9360480B2 (en) | 2016-06-07 |
JP4094674B2 (ja) | 2008-06-04 |
AU728357B2 (en) | 2001-01-04 |
WO1998023960A1 (en) | 1998-06-04 |
EP1152012B1 (de) | 2007-07-25 |
DE69710360D1 (de) | 2002-03-21 |
DE69737956T2 (de) | 2008-04-17 |
US20100203568A1 (en) | 2010-08-12 |
JP2001505568A (ja) | 2001-04-24 |
ATE368052T1 (de) | 2007-08-15 |
DE69710360T3 (de) | 2008-01-17 |
US20140087399A1 (en) | 2014-03-27 |
DE69710360T2 (de) | 2002-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69737956D1 (de) | CD8 Tuberkulose Impfstoffe | |
BR9406652A (pt) | Composição | |
DE69334076D1 (de) | Hla bindepeptide und ihre verwendungen | |
DE69733352D1 (de) | Hla-a2.1 bindende peptide und deren verwendung | |
ATE512666T1 (de) | Hla-bindende peptide und ihre verwendungen | |
TR199701252T1 (xx) | Bir saponin ve bir sterol i�eren a��lar. | |
PT807178E (pt) | Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose | |
ATE536187T1 (de) | Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen | |
ATE347599T1 (de) | Tuberkulose impfstoff | |
ATE87655T1 (de) | Markierer der t-zelle aktivierung. | |
NO20005050D0 (no) | Fusjonsproteiner fra Mycobacterium Tuberculosis-antigener og deres anvendelse | |
CY1107706T1 (el) | Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea) | |
BR0017136A (pt) | Peptìdeos de ligação ao hla e seus usos. | |
GB9409985D0 (en) | Vaccine against mycobacterial infections | |
EP1214088A4 (de) | Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe | |
ATE429247T1 (de) | Hla-bindende peptide und ihre verwendungen | |
DE69525058D1 (de) | Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle | |
TR199800575T1 (en) | Kemokin �-8'in k�sa formlar�. | |
NO20005081D0 (no) | Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav | |
BR9407357A (pt) | Novos tripeptideos utilizáveis em terapia cns e imune | |
DK469188D0 (da) | Fremgangsmaade og indretning til tilvejebringelse af personlig luftkonditionering | |
CY1108864T1 (el) | Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους | |
BR0016740A (pt) | Antìgenos de esporozoìto de cryptosporidium | |
KR940023996U (ko) | 이·미용용 중화제 분사기 | |
KR940018852U (ko) | 등산용 배낭의 에어 쿠션 장치 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |